9/21/2021 9:08:08 AM
Nektar Collaborates With Merck KGaA And Pfizer To Combine NKTR-255 With Avelumab In JAVELIN Bladder Medley Study
8/5/2021 4:16:50 PM
Nektar Therapeutics Q2 Loss/share $0.69 Vs. Loss $0.45 Year Ago
7/19/2021 9:01:57 AM
Nektar Appoints Dimitry Nuyten As SVP And Chief Medical Officer
5/18/2021 8:04:48 AM
Nektar Therapeutics Publishes Preclinical Data Of IL-15 Agonist, NKTR-255, In The Journal For ImmunoTherapy Of Cancer
5/6/2021 4:16:20 PM
Nektar Therapeutics Q1 Loss/Shr $0.68 Vs Loss $0.78 Last Year
2/25/2021 4:17:00 PM
Nektar Therapeutics Q4 Loss/share $0.65 Vs. Loss $0.64 Year Ago
2/17/2021 8:11:58 AM
Nektar Announces Agreement For Phase 2/3 Study Of Bempegaldesleukin In Combination With KEYTRUDA
2/17/2021 8:10:39 AM
Nektar Announces Collaboration With SFJ Pharma To Support Development Of Bempegaldesleukin In Head And Neck Cancer
1/5/2021 4:21:35 PM
Nektar Appoints Brian Kotzin As Interim Chief Medical Officer And Head Of Development
12/22/2020 8:31:46 AM
Nektar Therapeutics Enters Agreement With Healthcare Royalty To Sell ADYNOVATE And MOVANTIK Royalties For $150 Mln